CN108324706A - 改善认知功能和降低心率的方法 - Google Patents

改善认知功能和降低心率的方法 Download PDF

Info

Publication number
CN108324706A
CN108324706A CN201810349154.XA CN201810349154A CN108324706A CN 108324706 A CN108324706 A CN 108324706A CN 201810349154 A CN201810349154 A CN 201810349154A CN 108324706 A CN108324706 A CN 108324706A
Authority
CN
China
Prior art keywords
dha
acid
dosage form
unit dose
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810349154.XA
Other languages
English (en)
Chinese (zh)
Inventor
K·尤科-毛罗
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DSM IP Assets BV
Original Assignee
DSM IP Assets BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DSM IP Assets BV filed Critical DSM IP Assets BV
Publication of CN108324706A publication Critical patent/CN108324706A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/232—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having three or more double bonds, e.g. etretinate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Plant Substances (AREA)
CN201810349154.XA 2009-02-02 2010-02-02 改善认知功能和降低心率的方法 Pending CN108324706A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US14931009P 2009-02-02 2009-02-02
US61/149,310 2009-02-02
US18354809P 2009-06-02 2009-06-02
US61/183,548 2009-06-02
CN2010800157224A CN102365087A (zh) 2009-02-02 2010-02-02 改善认知功能和降低心率的方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN2010800157224A Division CN102365087A (zh) 2009-02-02 2010-02-02 改善认知功能和降低心率的方法

Publications (1)

Publication Number Publication Date
CN108324706A true CN108324706A (zh) 2018-07-27

Family

ID=42041547

Family Applications (3)

Application Number Title Priority Date Filing Date
CN201810349154.XA Pending CN108324706A (zh) 2009-02-02 2010-02-02 改善认知功能和降低心率的方法
CN2010800157224A Pending CN102365087A (zh) 2009-02-02 2010-02-02 改善认知功能和降低心率的方法
CN201410152946.XA Pending CN104042600A (zh) 2009-02-02 2010-02-02 改善认知功能和降低心率的方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
CN2010800157224A Pending CN102365087A (zh) 2009-02-02 2010-02-02 改善认知功能和降低心率的方法
CN201410152946.XA Pending CN104042600A (zh) 2009-02-02 2010-02-02 改善认知功能和降低心率的方法

Country Status (8)

Country Link
US (2) US20100203123A1 (https=)
EP (2) EP2939671A1 (https=)
JP (5) JP2012516852A (https=)
CN (3) CN108324706A (https=)
AU (2) AU2016201382A1 (https=)
CA (1) CA2751275A1 (https=)
HK (1) HK1202243A1 (https=)
WO (1) WO2010088700A1 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8207363B2 (en) 2009-03-19 2012-06-26 Martek Biosciences Corporation Thraustochytrids, fatty acid compositions, and methods of making and uses thereof
WO2011006144A1 (en) * 2009-07-10 2011-01-13 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid
CA2833219A1 (en) 2011-05-19 2012-11-22 The Regents Of The University Of California Nutraceutical composition comprising fisetin and docosahexaenotic acid useful in the treatment of cognitive decline
US20130084272A1 (en) * 2011-09-29 2013-04-04 Philippe Perrin Compositions, kits and methods for nutritional supplementation with twelve carbon chain fatty acids and twelve carbon chain acylglycerols
US8168611B1 (en) 2011-09-29 2012-05-01 Chemo S.A. France Compositions, kits and methods for nutrition supplementation
HK1213740A1 (zh) * 2013-03-15 2016-07-15 Inspyr Therapeutics, Inc. 制备抗癌症组合物的方法
FI3626806T3 (fi) 2013-12-20 2024-08-22 Mara Renewables Corp Menetelmiä öljyn talteenottamiseksi mikro-organismeista
TR201503136A2 (tr) * 2015-03-16 2016-09-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dronedaron ve esansiyel yağ asitlerinin farmasötik kompozisyonları.
US10851395B2 (en) 2016-06-10 2020-12-01 MARA Renewables Corporation Method of making lipids with improved cold flow properties
EP3559206B1 (en) 2016-12-22 2025-12-03 Mara Renewables Corporation Methods for producing biomass rich in dha, palmitic acid and protein using a eukaryotic microorganism
JP7101087B2 (ja) * 2018-09-05 2022-07-14 株式会社 伊藤園 軽度認知障害に対する緑茶成分の有効性評価方法
FR3092968B1 (fr) * 2019-02-22 2021-05-21 Microphyt Complement alimentaire
AU2020325063B2 (en) * 2019-08-08 2026-04-02 Swinburne University Of Technology Uses of long-chain polyunsaturated fatty acids
MX2022012322A (es) 2020-04-03 2022-11-10 Mara Renewables Corp Aceites microbianos con niveles altos de ácidos grasos omega-3.
DE102020115238A1 (de) * 2020-06-09 2021-12-09 Pm-International Ag Nahrungsergänzungsmittel und Nahrungsmittel
CN115867980A (zh) * 2020-07-02 2023-03-28 派尔疗法美国股份有限公司 用于生成和施用数字治疗安慰剂和伪物的系统、方法和设备
CA3204546A1 (en) * 2021-01-15 2022-07-21 Cambridge Cognition Limited Methods and systems of identifying individuals for perioperative neurocognitive disorder and/or post-viral cognitive impairment
WO2024155781A1 (en) * 2023-01-18 2024-07-25 Bioventures, Llc Method of preventing and treating alzheimer's disease and related dementias with drugs inhibiting the interaction between 14-3-3g protein and hexokinase-1 protein
WO2025100476A1 (ja) * 2023-11-10 2025-05-15 国立大学法人京都大学 生理機能改善用の組成物
JP2025079778A (ja) * 2023-11-10 2025-05-22 ダイドーグループホールディングス株式会社 生理機能改善用の組成物

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
US20060166935A1 (en) * 2005-01-24 2006-07-27 Morten Bryhn Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
WO2009002165A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving brain function

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5407957A (en) 1990-02-13 1995-04-18 Martek Corporation Production of docosahexaenoic acid by dinoflagellates
US20050027004A1 (en) * 1993-06-09 2005-02-03 Martek Biosciences Corporation Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
PT707487E (pt) * 1993-06-09 2004-08-31 Martek Biosciences Corp Metodos e composicoes farmaceuticas uteis no tratamento de disturbios neurologicos
EP0776356B1 (de) 1994-08-16 1999-06-30 Dr. Frische GmbH Verfahren zur gewinnung von nicht wasserlöslichen, nativen produkten aus nativen stoffgemengen mit hilfe der zentrifugalkraft
US6582941B1 (en) * 1995-04-17 2003-06-24 Japan As Represented By Director-General Of Agency Of Industrial Science And Technology Microorganisms capable of producing highly unsaturated fatty acids and process for producing highly unsaturated fatty acids by using the microorganisms
JP3985035B2 (ja) * 1995-09-14 2007-10-03 独立行政法人産業技術総合研究所 （ｎ−６）系ドコサペンタエン酸含有油脂ならびに該油脂の製造方法および用途
DE60012934T2 (de) 1999-02-26 2005-08-25 Martek Biosciences Corp. Verfahren zum Abtrennen von einem Docosahexaensäure enthaltenden Triglycerid aus einem Triglyceridgemisch
AU2001232786A1 (en) 2000-01-11 2001-07-24 Monsanto Company Process for making an enriched mixture of polyunsaturated fatty acid esters
CA2397655C (en) 2000-01-19 2012-06-05 Craig M. Ruecker Solventless extraction process
AU2001258705A1 (en) 2000-04-12 2001-10-23 Westfalia Separator Industry Gmbh Method for the fractionation of oil and polar lipid-containing native raw materials using alcohol and centrifugation
EP1392623A4 (en) 2001-05-14 2005-05-04 Martek Biosciences Corp PREPARATION AND USE OF A POLAR LIPID RICH FRACTION CONTAINING HIGHLY UNSATURATED OMEGA-3 AND / OR OMEGA-6 FATTY ACIDS FROM MICROBES, SEEDS OF GENETICALLY MODIFIED PLANTS AND MARINE ORGANISMS
JP4728561B2 (ja) 2001-05-14 2011-07-20 マーテック バイオサイエンシーズ コーポレーション 植物種子および微生物由来のステアリドン酸およびγ−リノレン酸を含む極性脂質リッチ画分の精製および使用方法
US9101151B2 (en) 2002-05-03 2015-08-11 Dsm Ip Assets B.V. High-quality lipids produced by enzymatic liberation from biomass
WO2006077495A1 (en) * 2005-01-24 2006-07-27 Pronova Biocare As Use of a fatty acid composition containing dha for the production of a medical product or a food stuff for the treatment of amyloidos-rerelated diseases
BRPI0613303A8 (pt) * 2005-05-23 2018-01-30 Massachusetts Inst Technology composições que contêm pufa e/ou uridina e métodos de uso das mesmas
BRPI0613358A8 (pt) * 2005-07-08 2017-12-26 Dsm Ip Assets Bv ácidos de gordura poli - insaturada para o tratamento da demência e condições relacionadas à pré-demência
AU2008269989B2 (en) 2007-06-29 2014-02-27 Dsm Ip Assets B.V. Production and purification of esters of polyunsaturated fatty acids
WO2011006144A1 (en) * 2009-07-10 2011-01-13 Martek Biosciences Corporation Methods of treating and preventing neurological disorders using docosahexaenoic acid

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003003981A2 (en) * 2001-07-05 2003-01-16 Vital Basics, Inc. Compositions for improving mental performance
US20060166935A1 (en) * 2005-01-24 2006-07-27 Morten Bryhn Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
WO2009002165A1 (en) * 2007-06-26 2008-12-31 N.V. Nutricia Lipid composition for improving brain function

Also Published As

Publication number Publication date
CN102365087A (zh) 2012-02-29
CA2751275A1 (en) 2010-08-05
CN104042600A (zh) 2014-09-17
HK1202243A1 (en) 2015-09-25
AU2017245327A1 (en) 2017-11-02
JP2020050675A (ja) 2020-04-02
JP2012516852A (ja) 2012-07-26
EP2939671A1 (en) 2015-11-04
EP2391361A1 (en) 2011-12-07
US20130172412A1 (en) 2013-07-04
US20100203123A1 (en) 2010-08-12
WO2010088700A1 (en) 2010-08-05
AU2010207929A1 (en) 2011-09-22
JP2018104477A (ja) 2018-07-05
JP2015143248A (ja) 2015-08-06
AU2016201382A1 (en) 2016-03-24
JP2022059063A (ja) 2022-04-12

Similar Documents

Publication Publication Date Title
CN108324706A (zh) 改善认知功能和降低心率的方法
US11052063B2 (en) Methods of reducing RLP-C
US20220313645A1 (en) Methods of treating hypertriglyceridemia
ES2661217T3 (es) Composiciones y métodos para reducir los triglicéridos sin aumentar los niveles de LDL-C en un sujeto en terapia simultánea con estatinas
US20100130608A1 (en) Compositions and methods for reducing triglyceride levels
US20200268702A1 (en) Methods of treating hypertriglyceridemia
Asztalos et al. Effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular disease risk factors: a randomized clinical trial
US20200061012A1 (en) Methods of treating hypertriglyceridemia
EP2596786B1 (en) Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
US20130137767A1 (en) Methods and Compositions for Treating Arthritis with Docosahexaenoic Acid
WO2013103958A1 (en) Compositions and methods for lowering levels of high-sensitivity (hs-crp) in a subject
EP1968567A1 (en) Omega 3 fatty acid formulations
WO2011109724A1 (en) Compositions and methods for treating and/or preventing cardiovascular disease
WO2014004861A2 (en) Methods of treating pediatric metabolic syndrome
US20110177061A1 (en) Methods of treating and preventing neurological disorders using docosahexaenoic acid
AU2010207929B2 (en) Methods for improving cognitive function and decreasing heart rate
Dahms et al. Safety of docosahexaenoic acid (DHA) administered as DHA ethyl ester in a 9-month toxicity study in dogs
Hoang et al. Comparing the cardiovascular risk-reducing effects of polyunsaturated fatty acids in fish oil and krill oil: A network meta-analysis
Harris et al. Increases in erythrocyte DHA are not associated with increases in LDL-cholesterol: Cooper center longitudinal study
US20110082205A1 (en) Docosahexaenoic Acid Gel Caps
AU2014202448B2 (en) Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia
Erglis et al. A new type of polyphenols-containing dietary supplement for correction of lipids and inflammatory markers in patients with coronary artery disease
AU2006331645B2 (en) Omega 3 fatty acid formulations
Horowitz Cholesterol Management: New Clinical Guidelines and Therapeutic Options

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180727

WD01 Invention patent application deemed withdrawn after publication